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Abstract
Familial Mediterranean Fever (FMF) is an inherited autoinflammatory disorder characterized by unprovoked episodes of
fever and inflammation. The associated gene, MEFV (Mediterranean Fever), is expressed primarily by cells of myeloid lineage
and encodes the protein pyrin/TRIM20/Marenostrin. The mechanism by which mutations in pyrin alter protein function to
cause episodic inflammation is controversial. To address this question, we have generated a mouse line lacking the Mefv
gene by removing a 21 kb fragment containing the entire Mefv locus. While the development of immune cell populations
appears normal in these animals, we show enhanced interleukin (IL) 1b release by Mefv2/2 macrophages in response to a
spectrum of inflammatory stimuli, including stimuli dependent on IL-1b processing by the NLRP1b, NLRP3 and NLRC4
inflammasomes. Caspase-1 activity, however, did not change under identical conditions. These results are consistent with a
model in which pyrin acts to limit the release of IL-1b generated by activation and assembly of inflammasomes in response
to subclinical immune challenges.
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Introduction
Mutations in MEFV predispose humans to Familial Mediterra-
nean Fever (FMF), a disease characterized by spontaneous
activation of the innate immune system in the absence of a
detectable pathogenic stimulus. Fever and acute abdominal pain
are the most common symptoms, but disease manifestations also
include arthritis, pleuritis, localized erythema, and amyloidosis of
the kidneys. The inflammation observed in FMF patients is
characterized by neutrophil influx to peripheral tissues and
increased serum levels of acute-phase reactant proteins and
cytokines [1]. Pharmacological inhibitors of IL-1b/IL-1 receptor
signaling are efficacious in the treatment of some patients,
supporting the hypothesis that pathophysiology of FMF is
mediated in part by this cytokine [2].
MEFV encodes a 781 a.a. cytoplasmic protein comprised of 5
domains: pyrin, b-Zip, B-Box, coiled-coiled, and PRY/SPRY
(B30.2), although this later domain is absent in the mouse protein.
The pyrin domain is of particular interest since this domain is
found in several proteins critical in IL-1b production [3]. Similar
to most cytokines, Il1b transcript levels are enhanced by cellular
stimulation with cytokines or pathogen-associated molecular
patterns (PAMPs) [4]. However, the Il1b gene does not encode
a leader peptide to facilitate transport and secretion of the protein
[5]. Instead, it is synthesized as an inactive pro protein which is
cleaved by the cysteine-aspartic acid protease caspase-1 (CASP-1)
to form mature IL-1b. Catalytic activity of CASP-1 also requires
removal of a regulatory domain, although in this case, this is
achieved through autocatalytic cleavage. Activation of CASP-1 is
observed after exposure of cells to both host-derived signals of
cellular stress or damage, called danger-associated molecular
patterns (DAMPs), and to PAMPS. These signals trigger the
assembly of inflammasomes, protein scaffolds nucleated by a
nucleotide-binding domain, leucine-rich repeat family (NLR)
protein. A number of NLRs are capable of assembling an
inflammasome in response to unique but overlapping DAMPS and
PAMPS. To date, these include NLRP3, NLRP1b, NLRC4,
NLRP2 and NLRP6 [6–11]. However, assembly of a CASP-1
activating inflammasome complex is not restricted to the NLR
family, as more recently, the protein absent in melanoma 2 (AIM2)
has been shown to contribute to CASP-1 activation and IL-1b
release in response to dsDNA [12].
In addition to the NLR/AIM2 protein, the inflammasome often
contains the protein adaptor ASC which facilitates the recruitment
of pro-caspase-1 to the complex [3]. Interaction between the pyrin
and card domains of various proteins is critical for inflammasome
assembly, both the self-association of the NLR proteins and the
recruitment of ASC and CASP-1 to the complex. It is, therefore,
not surprising that it has been suggested that proteins which
contain a PYD or CARD domain, yet lack other critical functional
domains, act as negative regulators of inflammasome assembly
[13]. Furthermore, a number of studies indicate that pyrin might
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function in a similar manner, with disease-associated mutations
resulting in reduced ability to limit inflammasome assembly [14-
17]. Such a model is consistent with the recessive pattern of
inheritance of the disease [18,19] and with previous findings that
pyrin can bind ASC, CASP-1, NLRPs 1-3, and IL-1b
[15,17,20,21].
Not all reports, however, support this model. Molecular
genetic reports of both the absence of individuals carrying null
MEFV alleles and the observation of disease in some individuals
believed to carry a wild-type allele, have led to the suggestion
that FMF is an autosomal dominant disease with variable
penetrance [22,23]. It has been posited that pyrin itself can
assemble a CASP-1 activating inflammasome, with the assembly
of the mutant pyrin inflammasome triggered by lower,
subclinical, levels of PAMPs/DAMPs [20,24–27]. Transfection
and knockdown studies provide limited clarification of the
function of pyrin. In some studies, pyrin increased IL-1b
release, while in other studies using similar strategies, cytokine
production was decreased [14–17,20,25–27]. Furthermore,
previous reports that MEFV expression is either increased,
decreased, or unchanged in FMF patients compared to healthy
controls complicates interpretations of the function of pyrin in
both homeostatic and inflammatory contexts [28].
To further examine the function of pyrin, we describe here the
generation of a mouse line carrying a null Mefv allele. This mouse
lacks the entire 21 kb locus. Using primary cells from this mouse
line, we show that pyrin negatively regulates IL-1b production in
response to inflammasome-dependent stimuli.
Materials and Methods
Mice
All experiments were conducted in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals. The protocol was approved by the Institu-
tional Animal Care and Use Committee guidelines of the
University of North Carolina at Chapel Hill (Permit Number:
10-181).
A targeting vector designed to remove the entire coding region of
Mefv was assembled from bacterial artificial chromosome bMQ133e1
(Geneservice, United Kingdom) that contains the Mefv genomic
region of the mouse strain 129S7/SvEv. Bam HI and Xba I
restriction digest sites were added at the 39 end of the Neor cassette.
The targeting vector was introduced into 129S6 derived embryonic
stem cells. Chimeric mice were mated with 129S6 mice. Bam-HI
digested DNA was assessed by Southern blot analysis using a 39 probe
created by PCR (primers: 59- GTGGTGGGTCTTCCTGTG -39
and 59- GGTCTCTGATGGGGTTGAAA -39) and a deleted
region (DR) probe (primers: 59-GCAGGGAGGCTTCAAG-
GACTTTAC -39 and 59- TCTCCTCCCCAATCAACGATGTTT
-39). For northern blot, RNA was isolated from recruited peritoneal
neutrophils using RNA Bee (Tel-test) and hybridized with
[a-32P]dCTP-labeled full-length Mefv and b-actin cDNA. Mice were
genotyped by PCR (primers: endogenous: 59- CTTTGGA-
GATTGCTGGCTGT -39, targeted: 59- AAATGCCTGCTCTT-
TACTGAAGG -39, common: 59- TCCAGGAAATGGAGA-
GATGG -39).
Casp-12/2 mice were generated as previously described [29].
Real-time PCR Analysis
RNA was harvested from bone marrow-derived macrophages
(BMMW), resident peritoneal macrophages (rpMW), and elicited
peritoneal macrophages (pMW). Total RNA was converted to
cDNA using High Capacity cDNA Reverse Transcription Kit.
TaqMan universal PCR master mix and recommended probes
were used to detect fluorescence by an ABI Prism 7900HT
detection system (Applied Biosystems). The probe for Mefv
(Mm00490258_m1) detects all known splice variants. Gene
expression was calculated as the relative expression of Mefv,
Il1b, or Il6 normalized by Gapdh or 18s.
In vitro Macrophage Activation Studies
Peritoneal cells were collected from mice by lavage and cultured
in RPMI media (Gibco) containing 10% FBS (Cellgro), 10 mM
HEPES (Gibco), L-glutamine, pen/strep, and 2b-mercaptoethanol
at 105 cells/well in a 96-well plate. Cells were activated as follow:
ATP, flagellin, muramyl dipeptide (MDP), TiO2: cells were primed
with 1 mg/ml LPS from Escherichia coli (Sigma) for 6 h follow by
stimulation with 1mM ATP for 30 min, 20 ng/ml flagellin for 2 h,
250 ng/ml each of lethal factor and protective antigen from
Bacillus anthracis (LT) for 3 h, or 10 mg/ml MDP and 5 mg/ml
titanium dioxide TiO2 for 24 h.
Aluminum hydroxide (Alum), silica, calcium pyrophosphate dihydrate
(CPPD): cells were incubated with 250 mg/ml Alum, 250 mg/ml
silica, or 100 mg/ml CPPD, together with 1 mg/ml LPS for 6 h.
Cell culture supernatants were collected and stored at 280uC.
After collection of media, cells were lysed and total protein was
measured.
Protein Analyses
IL-1b (eBioscience), IL-6 (eBioscience), and IL-18 (MBL
International) ELISA, lactate dehydrogenase, a marker for cell
death (LDH, Clontech) and total protein (BCA protein assay,
Thermo Scientific Pierce) protocols were followed as recom-
mended by the manufacturer. For western blot analysis, protein
was quantified by BCA assay (Thermo Scientific Pierce). Protein
was separated by SDS/PAGE, transferred onto a PVDF
membrane, and incubated with IL-1b (R&D Systems) or CASP-
1 (Upstate) antibodies.
In vivo LPS
Mice were treated with 2.5 mg/kg or 0.25 mg/kg of LPS
(serotypes 127:B5 and 055:B5, respectively) by i.p. injection.
Body temperature was measured with a rectal thermometer
probe. Mice were sacrificed at 20 h (2.5 mg/kg of LPS) or 24 h
(0.25 mg/kg of LPS). Weight loss was calculated using body
weights measured at 0 h and the time of harvest. The
peritoneal cavity was lavaged with 4 ml of PBS. Peritoneal cell
concentrations were assessed using a hemocytometer. Peritoneal
lavage fluid was used to determine IL-1b and TNFa
concentrations by ELISA (BD Biosciences) and myeloperoxidase
(MPO) by colorimetric assay.
FACS Analysis of Caspase-1 activity in vivo
Mefv+/+ and Mefv2/2 mice were dosed intratracheally with
10 ug Bacillus anthracis lethal toxin (LT) or PBS vehicle. Broncho-
alveolar lavage (BAL) fluid was collected 2 h after intratracheal
instillation. The vast majority of cells in the BAL were considered
macrophages based upon morphological criteria. Cells of the BAL
were stained with a fluorescently labeled CASP-1 inhibitor, FAM-
YVAD-FMK, according to manufacturer’s instructions (Cell
Technology). FACS analysis was performed using a Beckman
Coulter CyAn ADP Analyzer. Data were analyzed using FloJo
(TreeStar) software to determine the geometric mean of fluores-
cence intensities.
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Results
Generation of Mefv Null Mice and Characterization of
Immune Cell Populations
To generate a mouse line carrying a null Mefv allele, we
designed a targeting construct capable of deleting the entire Mefv
locus. Homologous recombination between this vector and the
endogenous gene resulted in deletion of all Mefv exons, the 5 kb
promoter region, and the intergenic region immediately 39 of the
39UTR (Figure 1a). Chimeras generated from targeted 129S6 ES
cell lines were crossed with 129S6 females to maintain the null
allele on this inbred genetic background. Inheritance of the
targeted locus was detected by Southern blot (Figure 1b) and
followed a Mendelian pattern. DNA from animals homozygous for
the targeted locus (Mefv2/2) was subjected to additional Southern
blot analysis to verify absence of the Mefv gene. As expected, DNA
from these pups failed to hybridize with probes corresponding to
various regions of the Mefv gene (Figure 1b and data not shown).
Moreover, Mefv transcripts could not be detected, either by real-
time PCR or northern blot analysis, in RNA prepared from
elicited peritoneal neutrophils of Mefv2/2 animals (Figure 1c and
data not shown).
Loss of Mefv expression did not impact the survival, growth, or
reproductive performance of the mice, nor could Mefv2/2 mice be
distinguished from littermates based on morphological or behav-
ioral criteria. No change in size and cellularity of the thymus,
spleen, or lymph nodes was apparent. Furthermore, analysis of the
cellular composition of these organs failed to identify a role for
Mefv in the development of lymphocytes or cells of myeloid lineage
(Table 1 and data not shown), despite the high level of expression
of Mefv in this later population. Mefv expression was easily detected
in bone marrow-derived macrophages. However, Mefv expression
was higher in resident peritoneal macrophages (rpMW) and the
expression is markedly induced in peritoneal macrophages
collected from the peritoneal cavity 72 hours after the induction
of peritonitis with the sterile immunostimulant, thioglycolate
(Figure 2a). Loss of Mefv did not alter the numbers of resident
macrophages or the recruitment of macrophages to the peritoneal
cavity in response to these inflammatory stimuli (data not shown).
Pyrin-deficient Mice Displayed Normal Responses to LPS
The N-terminal cleaved fragment of pyrin has been reported to
interact with IkB-a and the p65 subunit of NF-kB, increasing the
activity of this transcription factor [30]. If this model is correct, it is
reasonable to expect that the induction of NF-kB transcripts after
treatment of cells with inflammatory mediators such as LPS would
be attenuated in Mefv2/2 mice. To test this hypothesis, we
compared the mRNA levels of two NF-kB sensitive transcripts,
Il1b and Il6, in macrophages before and after exposure to LPS.
Basal levels of mRNA for both of these cytokines were similar in
the Mefv2/2 and control macrophages. As expected, treatment of
the cells with LPS for 24 hours resulted in a robust increase in
expression of these genes. However, the magnitude of the increase
in expression of Il1b and Il6 was not altered in cells lacking pyrin
(Figure 2b).
To address this point further, we examined the level of IL-6 and
IL-1b in the supernatant of cultures of rpMW before and after LPS
treatment. IL-6, similar to most cytokines, is released through a
classical secretion pathway [4]. Consistent with the increase in
mRNA levels, a dramatic increase in the level of IL-6 was
observed in the supernatants from the LPS-treated cells. No
difference, however, was observed in IL-6 levels in samples from
wild-type (WT) and pyrin-deficient cell cultures (Figure 2C).
Similar to IL-6, LPS results in an increase in expression of Il1b
mRNA, but efficient release of this cytokine requires processing of
the immature protein by CASP-1 [7]. Thus, not unexpectedly, the
level of IL-1b in the supernatant collected from macrophage
cultures is low, and while these levels increased significantly after
LPS treatment, the magnitude of this increase was small. Loss of
pyrin did not augment or attenuate the release of IL-1b by rpMW
either left untreated or following treatment with LPS (Figure 2D).
The presence of cytoplasmic enzyme lactate dehydrogenase (LDH)
in the cell supernatant can be used to quantitate cell death [31,32].
Using this criteria, survival of the macrophages, either under control
conditions or in the presence of LPS was not altered by the lack of
pyrin: levels of the cytoplasmic enzyme LDH in the supernatant did
not differ between samples collected from Mefv2/2 and WT cultures
(Figure 2E).
To further examine the impact of the loss of pyrin on the
response to endotoxin, we determined the impact of systemic
exposure of Mefv-deficient mice to LPS. At high doses, exposure to
endotoxin results in hypothermia, which is at least in part
dependent on elevated levels of NF-kB-sensitive cytokines such as
TNFa [14]. I.p. injection of LPS resulted in a rapid drop in
temperature, with core body temperature reaching a minimum at
2 h after treatment. Both the magnitude of the drop in
temperature, as well as the kinetics of the temperature change
and subsequent recovery of the animals was similar in the Mefv2/2
and control cohorts. No difference was observed in the cryogenic
response of the Mefv2/2 and wild-type control animals to i.p. LPS
at both doses of endotoxin examined (Figure 2F and G). In addition
to hypothermia, LPS treatment results in a measurable drop in
body weight accompanied by local neutrophilic inflammation.
Neither a change in body weight or the number and composition
of cells recruited to the peritoneal cavity distinguished the Mefv2/2
mice from littermate control animals (Table 2).
NLRP3 Inflammasome-dependent IL-1b Production is
Increased in Mefv-deficient Macrophages
To determine if a loss of pyrin modulates inflammasome-
mediated IL-1b production, WT and Mefv2/2 rpMW were
exposed to a variety of elicitors that induce NLRP3 inflamma-
some-dependent IL-1b production. Cells were pre-treated with
LPS to induce IL-1b transcription and then stimulated with one of
the following NLRP3 inflammasome elicitors: titanium dioxide
(TiO2), aluminum hydroxide (Alum), calcium pyrophosphate
dehydrate crystals (CPPD), silica, or ATP [6,33]. IL-1b and IL-6
levels in the cell supernatants were determined by ELISA. We also
activated cells with muramyl dipeptide (MDP) and MDP with
TiO2. MDP alone and MDP plus TiO2 were reported to activate
both NLRP1 and NLRP3 inflammasomes [7,33]. However, recent
evidence suggests that MDP activates only the NLRP3 inflamma-
some [29]. As expected, treatment of cells with compounds that
trigger assembly of the NLRP3 inflammasome resulted in
substantial increase in the levels of extracellular IL-1b, in compar-
ison to cultures treated with LPS alone. In addition, in all cases,
higher IL-1b cytokine levels were measured in supernatants
collected from Mefv2/2 cultures compared to those collected from
similarly treated WT cultures. The magnitude of the increase in
the levels of IL-1b in Mefv2/2 cultures compared to controls
varied depending on the stimulus, ranging from an increase of 1.5-
fold in cells exposed to MDP and silica to an increase of almost 5-
fold in the response of Mefv2/2 cells to Alum (Figure 3A). No
difference was observed in the levels of IL-6 present in the samples
from WT and Mefv2/2 cultures (Figure 3B). Both mature and pro-
IL-1b can be released into the supernatant after cell death, and
most ELISAs do not bind exclusively to the mature protein. It is
therefore possible that the increase in IL-1b in samples collected
Pyrin Negatively Regulates IL-1b
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from Mefv2/2 cultures reflects an increase in cell death. To
address this question, we measured levels of LDH in the
supernatant. Many of the agents used to stimulate NLRP3
assembly decrease cell viability [34], and the magnitude of this
decrease was dependent on the agent used to elicit the
inflammasome, but viability was not influenced by the absence
of pyrin: LDH levels did not differ significantly between Mefv2/2
and WT macrophage cultures (Figure 3C).
Negative Regulation of IL-1b Production is not Limited to
the NLRP3 Inflammasome
CASP-1 activation and IL-1b release is also observed after
exposure of macrophages to agents that mediate the assembly of
NLRC4 and NLRP1b -containing inflammasomes [7]. We
therefore asked whether a loss of pyrin impacts only NLRP3-
mediated IL-1b release or whether it also modulates IL-1b release
secondary to assembly of these inflammasomes. WT and Mefv2/2
rpMW were treated with LPS and exposed to either flagellin,
known to elicit the NLRC4 containing inflammasome or Bacillus
anthracis (anthrax) lethal toxin (LT), activating NLRP1b containing
inflammasome in sensitive strains. Significantly higher levels of IL-
1b were observed in samples collected from cultures of Mefv2/2
macrophages compared to similarly treated WT controls
(Figure 4A). In contrast, IL-6 and LDH levels in supernatants
collected from WT and Mefv2/2 cultures were similar (Figure 4B
and C).
CASP-1 Activity is not Elevated in Mefv-deficient
Macrophages
Thus far, our results are consistent with two hypothetical
models. In the first, pyrin affects pro-IL-1b processing by
inhibiting activity of the inflammasome complexes. This could
occur either by regulating an upstream event common to NLRP3,
NLRP1b, and NLRC4 inflammasome assembly or by directly
inhibiting assembly and activity of the inflammasome complexes
themselves. In the second model, pyrin regulates release of mature
Figure 1. Generation of Mefv2/2 mice. A, Schematic showing the endogenous Mefv locus, gene-targeting construct, and targeted locus after
homologous recombination with the targeting construct. Upon homologous recombination, the entire coding region and 5 kb on either side of the
Mefv gene was replaced with a selectable neomycin resistance (neor) gene. Exons are depicted as filled boxes. The genomic fragment used in
Southern blot analysis is indicated as the 39 probe. B, Southern blot was used to screen offspring generated by the intercross of Mefv+/2 mice. The 39
probe detects a BamHI restriction fragment that is diagnostic of proper integration of the targeting construct at the endogenous Mefv locus (upper
panel). The deleted region (DR) probe corresponds to DNA in exon 2 and identifies a region deleted during homologous recombination (lower panel)
C, Northern blot analysis of RNA from Mefv+/+ and Mefv2/2 mice. A full-length Mefv cDNA probe was used to detect endogenous expression of Mefv
in elicited peritoneal neutrophils. Several bands were detected in the WT sample, which is consistent with the presence of multiple splice variants of
Mefv. The two most intense bands are shown. All bands are absent in Mefv2/2 mice. A probe specific to b-actin confirms equal loading of the RNA
samples.
doi:10.1371/journal.pone.0051105.g001
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IL-1b from macrophages subsequent to inflammasome activity.
To address these possibilities, we asked if inflammasome-stimu-
lated CASP-1 activity was altered in Mefv2/2 macrophages.
Macrophages were treated with LPS/ATP, and levels of pro-
caspase-1 and processed CASP-1 (p20) were assessed by western
blot analysis. As expected, LPS/ATP induced processing of
CASP-1, which could be detected in cell lysates and in media
collected from the macrophage cell cultures. The levels of
processed CASP-1, and the levels of pro-caspase-1 in the cell
lysates, did not differ between wild type and Mefv2/2 cultures.
CASP-1 activation was accompanied by processing and release of
mature IL-1b, as detected by western blot in the culture media of
the macrophages. Similar to measurements of IL-1b shown in
Figure 3A, an increased amount of IL-1b was detected in the
media from Mefv2/2 cells compared to wild-type cells (Figure 5A).
To further address CASP-1 activation, the activity of CASP-1 was
determined by using a fluorescently labeled inhibitor for CASP-1
(FAM-YVAD-FMK). Mice were exposed to Bacillus anthracis lethal
toxin (LT) or PBS vehicle by intratracheal (i.t.) instillation.
Bronchoalveolar lavage fluid (BAL) was collected at 2 h post-
treatment, and cells of the BAL were assessed by FACS analysis to
detect CASP-1 activity. CASP-1 activity increased following LT
Figure 2. Loss of Mefv does not affect the response to LPS. A, Relative expression of Mefv in bone marrow-derived macrophages (BMMW),
resting peritoneal macrophages (rpMW), and elicited peritoneal macrophages (pMW) from WT mice was detected by real-time PCR. n $3 mice per cell
type. Data are expressed as relative expression normalized to Gapdh and BMMW. B-D, rpMW from Mefv+/+ and Mefv2/2 littermate mice were untreated
or treated with 1 mg/mL LPS for 24 h. B, Il1b and Il6 expression at the transcript level is expressed as fold induced by LPS treatment. n = 3 mice per
genotype. C-E, Concentration of IL-6 and IL-1b in supernatants from LPS-treated rpMW cultures as determined by ELISA. n = 6 mice per genotype. E,
The concentration of lactate dehydrogenase (LDH) released into cell supernatants was used as an indicator of cell death. WT and Mefv2/2 mice were
treated with 2.5 mg/kg (F, n = 8 WT and 5 Mefv2/2 mice) or 0.25 mg/kg (G, n = 18 and 19) crude LPS by i.p. injection at time 0 h, as indicated by
arrows. Rectal temperature at the indicated times is shown in F and G.
doi:10.1371/journal.pone.0051105.g002
Table 1. Analysis of blood collected from Mefv+/+ and Mefv2/2
mice.
Genotype Mefv+/+ Mefv2/2
WBC (103/ml) 1.7160.28 2.1260.35
RBC (106/ml) 8.2960.16 8.3460.24
PLT (103/ml) 238.1629.55 285.5631.61
LYMPH (%) 73.4763.29 67.2566.08
GRAN (%) 17.0862.13 23.7260.65
MONO (%) 10.5060.65 10.0360.65
HCT (%) 45.2960.98 45.7361.09
HGB (g/100 ml) 13.7960.25 13.9060.30
Blood was collected by cardiac puncture. Whole blood containing 5 mM EDTA
was used for analysis on the Heska Hematology Analyzer by the Animal Clinical
Chemistry and Gene Expression Laboratory at UNC-Chapel Hill. n = 13 and 13
mice. WBC- white blood cells, RBC- red blood cells, PLT- platelets, LYMPH –
lymphocytes, GRAN – granulocytes, MONO – monocytes, HCT - hematocrit,
HGB hemoglobin. Differences between Mefv+/+ and Mefv2/2 were not
statistically significant.
doi:10.1371/journal.pone.0051105.t001
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treatment in both wild-type and Mefv2/2 alveolar macrophages,
and furthermore, CASP-1 activity did not differ between wild-type
and Mefv2/2 mice. To ensure the specificity of our assay for
measuring CASP-1 activity, Casp12/2 mice were also evaluated,
and as expected, no CASP-1 activity was induced in these mice
(Figure 5C). Next, we addressed whether or not the inhibitory
effect of pyrin extended to IL-18, another IL-1 family cytokine that
is processed and released from cells through pathways common to
IL-1b. Mefv2/2 macrophage cultures exposed to inflammasome
stimuli had elevated levels of IL-18 protein in the cell culture
supernatant compared to wild-type macrophages, thus mimicking
IL-1b levels (Figure 5D).
Discussion
We describe here the generation of a mouse in which the entire
pyrin gene is excised. Although a more difficult mutation to
generate, this strategy ensures the loss of not only the primary Mefv
transcript but also transcripts initiated from internal promoters
Table 2. Inflammatory response in Mefv+/+ and Mefv2/2 mice after LPS treatment.
Genotype LPS dose (mg/kg) Weight loss (%) Peritoneal cells (106) MPO (ng/ml)
Mefv+/+ 2.5 5.7460.5 38.1863.4 133.066.07
Mefv2/2 2.5 5.2060.61 36.4563.2 138.3610.54
Mefv+/+ 0.25 5.5460.65 3.2760.35 n.a
Mefv2/2 0.25 5.0260.44 4.1260.64 n.a
The body weight lost was measured between 0 h and 20 h post-LPS treatment, immune cells present in the peritoneal lavage fluid, and MPO activity as a measure of
neutrophil presence in lavage samples were evaluated 20 h post-LPS treatment. For body temperature changes, see Figure 2F, G. n.a. not analyzed. n = 18. Differences
between Mefv+/+ and Mefv2/2 mice within each dose of LPS treatment were not statistically significant.
doi:10.1371/journal.pone.0051105.t002
Figure 3. A loss of pyrin causes increased IL-1b protein levels in
response to NLRP3 inflammasome stimuli. rpMWs from Mefv+/+
and Mefv2/2 littermate mice were exposed to LPS and the indicated
stimuli as described in the method section. The concentration of IL-1b,
A, and IL-6, B, cytokines in cell culture supernatants was determined by
ELISA. C, LDH protein levels detected in cell supernatants. The total
protein of cell lysates was measured to verify equivalent plating of cells.
TiO2, titanium dioxide; MDP, muramyl dipeptide; Alum, aluminum
hydroxide; CPPD, calcium pyrophosphate dihydrate; ATP, adenosine 59
triphosphate. n = 6 mice per genotype. A student’s t test was used to
calculate p values for WT versus Mefv2/2 cultures. #, p,0.05; *, p#0.01
**, p#0.001, ***, p,0.0001.
doi:10.1371/journal.pone.0051105.g003
Figure 4. A loss of pyrin causes increased IL-1b release in
response to NLRC4 and NLRP1b stimuli. rpMWs from Mefv+/+ and
Mefv2/2 littermate mice were exposed to LPS and the indicated stimuli
as indicated in the method section. The concentration of IL-1b, A, and
IL-6, B, cytokines in cell culture supernatants was determined by ELISA.
C, LDH protein levels detected in cell supernatants. The total protein of
cell lysates was measured to verify equivalent plating of cells. LT, lethal
toxin of Bacillus anthracis. n = 6 mice per genotype. Results are
representative of at least 4 independent experiments. A student’s t
test was used to calculate p values for WT versus Mefv2/2 cultures. #,
p,0.05; *, p#0.01.
doi:10.1371/journal.pone.0051105.g004
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and splice variants from the Mefv locus. Thus, proteins containing
all or a subset of the many functional domains of pyrin cannot be
generated from this modified locus. Using these mice, we show a
marked change in the response of primary macrophages to a
number of inflammatory stimuli; specifically, a significant increase
in the release of IL-1b observed in cultures derived from Mefv2/2
mice in comparison to WT mice.
Since the discovery of the genetic lesions which cause FMF,
numerous models have emerged that attempt to incorporate
information gleaned from the genetic and clinical characteristics of
the disease, from the structure of the protein and its pattern of
expression, and from studies of the gene in model systems. One
model suggests that pyrin is a substrate for CASP-1, and the N-
terminal fragment of pyrin potentiates inflammation by interacting
with proteins of the NF-kB pathway. An increased ratio of cleaved
to intact protein was detected in clinical samples from FMF
patients [30]. However, other investigators have not observed
increased NF-kB-dependent luciferase activity following overex-
pression of full-length MEFV [16,20]. Our studies of mouse
macrophages lacking pyrin do not support a role for pyrin in
activity of the NF-kB pathway, although more extensive studies
are required. An increase in expression of NF-kB sensitive
transcripts was not observed in Mefv2/2 cells in a naı̈ve state or
after exposure to LPS. As expected, i.p. injection of LPS resulted in
an acute peritonitis characterized by a rapid drop in body
temperature and accumulation of inflammatory cells in the
peritoneal cavity. However, again, no difference was observed in
the response of the mutant mice compared to control littermates.
The phenotype of the Mefv null mice differs in some aspects
from those reported previously for mice carrying a disrupted Mefv
locus. Macrophages from these mice were shown to release more
IL-1b than wild type cells. In addition, these animals displayed an
exaggerated cryogenic response to low-dose LPS, and an increase
in morbidity upon exposure to high-dose LPS or LPS and D-Gal.
An increase in the number of inflammatory cells recovered from
peritoneal lavage fluid was observed in these mice after exposure
to thioglycolate. Furthermore, apoptosis was impaired in macro-
phages collected from animals homozygous for the targeted locus
[14]. In contrast, we did not observe an increase in the release of
IL-1b from Mefv2/2 cells treated with LPS alone, and the response
Figure 5. Caspase-1 (CASP-1) activity is not elevated in Mefv2/2 macrophages. A, rpMWs from Mefv+/+ and Mefv2/2 littermate mice were
exposed to LPS and ATP as indicated in the method section. Levels of caspase-1 (upper panel) and IL-1b (middle panel) were detected by western
blot in cell lysates (lanes 1 and 2) and cell culture supernatant (lanes 3 and 4). An equivalent amount of total protein was loaded in each lane. The
amount of protein in the lysate and supernatant was verified by staining with Ponceau S, major protein band is shown (lower panel). B and C, Mefv+/+,
Mefv2/2, and Casp12/2 mice were treated with 10 mg of lethal toxin (LT) or PBS vehicle alone by intratracheal instillation and bronchoalveolar lavage
(BAL) was collected at 2 h after treatment. Cells from the BAL were stained with fluorescently labeled CASP-1 inhibitor (FLICA), FAM-YVAD-FMK. Cells
were analyzed via flow cytometry. B, Data is expressed as the mean of the fluorescence intensity (MFI). C, A representative plot of the fluorescence
intensity of LT or vehicle-treated cell populations. D, rpMWs from Mefv+/+ and Mefv2/2 littermate mice were treated with LPS and the indicated stimuli
as in Figures 3 and 4. The concentration of IL-18 in cell culture supernatants was determined by ELISA. A student’s t test was used to calculate p
values for Mefv+/+ versus Mefv2/2 cultures. #, p,0.05; *, p,0.01.
doi:10.1371/journal.pone.0051105.g005
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of the Mefv2/2 animals to LPS delivered i.p. could not be
distinguished from that of the controls. We also failed to detect any
change in the survival of Mefv null cells: no difference in the rate of
cell death was observed in cultured macrophages, or in the
number of cells surviving after stimulation of these cultures with
inflammatory mediators. In addition, ex vivo survival of recruited
peritoneal neutrophils lacking pyrin was not altered (data not
shown). One explanation for the differences between the mutant
Mefv line characterized in this earlier report and the line described
here is that in the former, a Mefv transcript and a truncated pyrin
protein were created by the targeted allele. In fact, the level of this
truncated protein, based on western analysis, appeared to be
higher than that observed for the native protein. It is possible that
this truncated protein conferred unique functions not observed in
mice carrying a null allele.
While we did not observe an increase in the IL-1b release by
macrophages in response to LPS alone by cells lacking pyrin,
increased levels of IL-1b were detected in the culture media after
stimulation of these mutant cells with agents that lead to
inflammasome assembly. The increase in IL-1b levels was
observed in supernatants collected from cells stimulated with
agents known to trigger assembly of NLRP3, NLRP1b, and
NLRC4 inflammasomes. Increased release of IL-1b from cells in
response to all of the tested inflammatory stimuli is inconsistent
with a model in which pyrin modulates IL-1b production by
regulating the assembly of a specific inflammasome, such as the
NLRP3 inflammasome. It is unlikely that pyrin acts to block ASC
or CASP-1 association with the inflammasome, because no
alteration in CASP-1 activity was observed between Mefv2/2
and wild-type cells (Figure 5A–C). Our results differ from studies
carried out with a human monocyte/macrophage cell line and
PBMCs in which silencing of the MEFV transcript suppressed
secretion of IL-1b [25,26], and from transfection studies in which
overexpression of pyrin increased CASP-1 activity and IL-1b
release [20]. However, our results are consistent with models in
which pyrin acts as a negative regulator of innate immune
pathways, and with a genetic model in which pyrin mutations
causing FMF represent loss-of-function mutations. In opposition to
the studies mentioned above, silencing of MEFV has been shown
to increase IL-1b release from a human monocyte/macrophage
cell line [15,17]. This model is also supported by transfection
studies in which wild-type pyrin inhibited pro-IL-1b processing in
macrophage cell lines, whereas the FMF-associated alleles proved
less active in these assays [14,15].
It is becoming increasingly apparent that production of IL-1b is
regulated at many different levels, and that the relative importance
of these mechanism(s) is likely dependent on many factors
including the cell type, its local environment, and the nature of
the stimuli [35]. For example, recently, induction of autophagy by
rapamycin was reported to result in degradation of pro-IL-1b and
reduced secretion of IL-1b [36]. Interestingly, in one study,
examination of PMNs from FMF patients revealed a gene
expression pattern consistent with impaired basal autophagy
[37], raising the possibility that increased IL-1b levels in FMF
patients and the increase in IL-1b release by the Mefv2/2
macrophages reflect a defect in regulation of cellular levels of
pro-IL-1b. Many other means by which pyrin could modulate
release of IL-1b are apparent. For example, alteration in the
uptake of particulate matter and/or decrease in lysosomal stability
could increase IL-1b maturation in response to many stimuli [7].
In models of gout, crystal-induced IL-1b production has been
shown to be affected by Cathepsin B inhibitors that prevent
lysosomal instability [38], and crystal-induced IL-1b production
can be blocked by colchicine, a prophylactic drug for FMF
patients [39]. Alternatively, pyrin may regulate the trafficking or
release of vesicles containing mature IL-1b and IL-18, a process
that is poorly understood [5,40,41]. This hypothetical model is
consistent with our finding that levels of released IL-1b and IL-18
protein are higher in Mefv2/2 cultures compared to wild-type
despite similar levels of CASP-1 activity in Mefv2/2 and control
macrophages. In previous studies, pyrin was shown to interact
both directly and indirectly with cytoskeletal elements, which are
necessary for vesicle trafficking and release [42,43]. Pyrin has been
shown to bind directly to microtubules [44] and to actin [44,45].
Furthermore, it was previously shown that VASP and Arp3
proteins, which are important in actin polymerization, co-
immunoprecipitate with pyrin [45]. Pyrin also binds to proline-
serine-threonine phosphatase interacting protein 1 (PSTPIP1)
[27,46], and PSTPIP1 binds to PTP-PEST, which is a scaffolding
protein that associates with actin through the protein WASP [42].
Mutations in PSTPIP1 are associated with PAPA syndrome, an
autoinflammatory disorder similar to FMF, further supporting a
functional role of this pathway in inflammation. Together, these
data support a hypothesis that pyrin regulates trafficking or release
of vesicles containing IL-1b and IL-18. Further studies will be
required to identify at which of these many steps pyrin acts to limit
release of IL-1b and IL-18.
During the preparation of this manuscript, an additional mouse
line carrying a mutant Mefv2/2 gene has been reported. No
difference in the release of IL-1b by macrophages after treatment
with LPS or LPS and ATP, after infection with Salmonella
typhimurium, or after transfection of DNA was reported [24]. A
number of explanations for these differences are possible. First,
while our studies use mature peritoneal macrophages which
express high levels of pyrin (Figure 1A), Chae, et al. examine IL-1b
production in bone marrow-derived macrophages. As cultured
bone marrow-derived macrophages express very low levels of
pyrin, the impact of the loss of this protein on IL-1b processing
and/or release might not be as apparent with this cell type as on
comparison of cells with higher levels of expression. In addition,
the two studies use mice of differing genetic backgrounds: those
reported here carried out entirely with co-isogenic 129S6 mouse
lines, while those of Chae and colleagues used N6 B6.129 animals.
It is possible that the regulatory role of pyrin might be more
apparent on some genetic backgrounds. In particular, caspase-4 is
not functional in 129 genetic background.
The demonstration here that loss of pyrin can result in increase
in IL-1b release is consistent with the original designation of FMF
as a recessive genetic disorder. However, perhaps for no other
autoinflammatory disorder is the validity of extrapolating results
from mouse studies more subject to scrutiny than for FMF. Pyrin
encoded by the mouse gene lacks the C-terminal domain, termed
B30.2, that is present in the human protein. This complicates
comparison of gene function, not only because numerous functions
including interaction with CASP-1, NLRPs1-3, and IL-1b have
been assigned to this domain [17], but also because the majority of
the FMF mutations are located in this C-terminal region [14]. In
addition, major differences in the regulation of the gene have been
noted between human and mouse: while the mouse gene is
induced by IL-4 [14], this cytokine inhibits expression of the
human ortholog [47]. These differences raise the possibility that
one or more functions of pyrin is unique to the human protein and
is therefore difficult to model in the mouse. Thus, until novel
methods and reagents are developed for addressing this limitation,
we can only ascertain that pyrin can act to limit the activity of
proinflammatory pathways, namely the release of IL-1b by
macrophages, in at least some species.
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